胶囊内镜对预防克罗恩病术后复发的影响
这项回顾性队列研究纳入术后无药理预防的无症状克罗恩病患者,组1(37例)在术后1年内接受回结肠镜联合胶囊内镜(CE),组2(46例)仅接受回结肠镜。CE可发现回结肠镜漏诊的复发并指导启动药理治疗;组1总临床复发率为2.7%(1/37),低于组2的21.7%(10/46),差异有统计学意义(P = .019)。
要点
- 术后无症状克罗恩病患者中,CE可发现回结肠镜范围外或漏诊的内镜下复发。
- 回结肠镜判断缓解且经CE确认者,可维持无药理预防且无临床复发。
- 组1总临床复发率2.7%(1/37)低于组2的21.7%(10/46),P = .019。
核心结论
- 若回结肠镜判断的内镜下缓解经CE确认,患者可维持无药理预防;若CE检测到回结肠镜范围外的复发,则需要启动积极的药理治疗。
研究设计与样本
- 回顾性队列研究,组1为37例术后1年内接受回结肠镜联合CE的患者,组2为46例仅接受回结肠镜的患者。
主要发现
- 组1中所有回结肠镜发现复发的患者,CE也均发现复发;CE另检出11例回结肠镜漏诊的内镜下复发。
- 组1中回结肠镜判断的内镜下缓解经CE在13例中确认;1年后该24例均维持内镜下缓解,无临床复发。
- 组2中回结肠镜判断缓解者,1年后9/31例出现回结肠镜判断的复发和临床复发。
- 总临床复发率组1为2.7%(1/37),组2为21.7%(10/46),P = .019。
关键数值与推荐
- 经回结肠镜或CE检测到内镜下复发的患者,接受硫唑嘌呤或英夫利西单抗药理治疗。
临床怎么用
- 作者认为,回结肠镜判断的内镜下缓解经CE确认后,患者可维持无药理预防;CE检测到回结肠镜范围外的复发时,需要启动积极的药理治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Capsule endoscopy (CE) can detect lesions outside the scope of ileocolonoscopy in postoperative patients with Crohn's disease (CD). However, the impact of such findings on patient outcomes remains unknown. This study is intended to evaluate the impact of CE findings on clinical management and outcomes in asymptomatic patients with CD without pharmacologic prophylaxis after ileocolonic resection. METHODS: In this retrospective cohort study, 37 patients (group 1) received ileocolonoscopy together with CE within 1 year after surgery, whereas 46 patients (group 2) only received ileocolonoscopy. Patients with endoscopic recurrence detected by either ileocolonoscopy or CE received pharmacologic therapy with azathioprine or infliximab. One year later, disease activity was re-evaluated. RESULTS: In group 1, all patients with ileocolonoscopy-identified recurrence also had CE-identified recurrence. In addition, CE detected endoscopic recurrence in 11 patients missed by ileocolonoscopy. Endoscopic remission identified by ileocolonoscopy was confirmed by CE in 13 patients. One year later, endoscopic remission identified by ileocolonoscopy was maintained in all 24 patients, and none had clinical recurrence. Conversely, in group 2, of those with ileocolonoscopy-identified remission, both ileocolonoscopy-identified recurrence and clinical recurrence occurred in 9 of 31 patients 1 year later. The total clinical recurrence rate was 2.7% (1/37) in group 1 versus 21.7% (10/46) in group 2 (P = .019). CONCLUSIONS: If endoscopic remission identified by ileocolonoscopy was confirmed by CE, patients could remain free of pharmacologic prophylaxis. If recurrence outside the scope of ileocolonoscopy was detected by CE, initiation of active pharmacologic therapy would be needed.
引用
- Han ZM, Qiao WG, Ai XY, et al. Impact of capsule endoscopy on prevention of postoperative recurrence of Crohn's disease. Gastrointest Endosc. 2018. PMID: 29355520. doi:10.1016/j.gie.2018.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。